RHÖN-KLINIKUM Aktiengesellschaft
ISIN: DE0007042301
WKN: 704230
08 August 2024 09:00AM

EQS-News: First half of 2024: RHÖN-KLINIKUM AG continues good business performance – outlook confirmed

RHÖN-KLINIKUM Aktiengesellschaft · ISIN: DE0007042301 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 1963561

EQS-News: RHÖN-KLINIKUM Aktiengesellschaft / Key word(s): Half Year Results/Miscellaneous
First half of 2024: RHÖN-KLINIKUM AG continues good business performance – outlook confirmed

08.08.2024 / 09:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Corporate News

Bad Neustadt a. d. Saale | 8 August 2024

First half of 2024: RHÖN-KLINIKUM AG continues good business performance –
outlook confirmed

RHÖN-KLINIKUM AG closed the first half of 2024 with a 6.5% increase in revenues to 775.5 million euros (H1 2023: 728.2 million euros). Despite a challenging market environment, consolidated profit increased by 68.9% to reach EUR 20.6 million (H1 2023: EUR 12.2 million). From January to June 2024 a total of 463,111 patients were treated on an inpatient and outpatient basis in the Group’s hospitals and medical care centres, 3.8% more compared with the same period of the previous year (H1 2023: 446,022).

At 49.1 million euros, EBITDA was above the previous year’s level (H1 2023: 45.2 million euros). Materials and consumables used increased as a result of higher purchasing prices and the provision of material cost-intensive services to 266.2 million euros (H1 2023: 237.0 million euros).

“RHÖN-KLINIKUM AG is a sound, efficient and economically responsible company. Our five hospital sites
in the federal states of Bavaria, Brandenburg, Hesse and Thuringia are first-class, highly specialised
facilities which continue to show a solid performance. We therefore see ourselves well prepared for the impending healthcare reform”, said Prof Dr. Tobias Kaltenbach, chairman of the Board of Management of RHÖN-KLINIKUM AG.


Outlook for 2024 confirmed

For the current financial year, RHÖN-KLINIKUM AG continues to expect revenues of 1.6 billion euros within
a range of plus or minus 5%. For earnings before interest, tax and depreciation/amortisation (EBITDA),
a level of between 110 million euros and 120 million euros is expected.

The outlook is subject to considerable uncertainties in connection with the numerous global crises in the form of inflation and price increases and any regulatory measures impacting our remuneration structure
in 2024.
 

The 2024 Half-Year Report is published on the Internet.
 

RHÖN-KLINIKUM AG is one of the largest healthcare providers in Germany. The hospitals offer excellent medical care with a direct tie-in to universities and research facilities. Each year some 882,000 patients are treated at our five sites – RHÖN-KLINIKUM Campus Bad Neustadt, Klinikum Frankfurt (Oder), Universitätsklinikum Gießen and Universitätsklinikum Marburg (UKGM) as well as Zentralklinik Bad Berka. The Company employs over 18,200 persons. The innovative RHÖN Campus approach committed to cross-sector and future-oriented healthcare delivery in rural areas, the steadfast continuation of the gradual digital transformation within the Company as well as the strategic partnership with Asklepios are key elements of our corporate strategy. RHÖN-KLINIKUM AG is an independent Company operating under the umbrella of Asklepios Kliniken GmbH & Co. KGaA. www.rhoen-klinikum-ag.com

Contact:

RHÖN-KLINIKUM AG | Head of Corporate Finance, Treasury, Investor Relations and Sustainability
Julian Schmitt | T. +49 9771 65-12250 | julian.schmitt@rhoen-klinikum-ag.com

RHÖN-KLINIKUM AG | Schlossplatz 1 | D-97616 Bad Neustadt a. d. Saale

 



08.08.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: RHÖN-KLINIKUM Aktiengesellschaft
Salzburger Leite 1
97616 Bad Neustadt a. d. Saale
Germany
Phone: +49 (0)9771 - 65-0
Fax: +49 (0)9771 - 97 467
E-mail: rka@rhoen-klinikum-ag.com
Internet: www.rhoen-klinikum-ag.com
ISIN: DE0007042301
WKN: 704230
Listed: Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange
EQS News ID: 1963561

 
End of News EQS News Service

1963561  08.08.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1963561&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2018 2019 2020 2021 2022 2023 2024e
Sales1 1.232,91 1.303,90 1.360,16 1.402,01 1.446,09 1.463,98 1.620,00
EBITDA1,2 125,54 125,33 80,23 101,16 105,65 105,88 117,00
EBITDA-Margin3 10,18 9,61 5,90 7,22 7,31 7,23 7,22
EBIT1,4 64,94 56,80 10,60 30,52 36,11 40,40 53,00
EBIT-Margin5 5,27 4,36 0,78 2,18 2,50 2,76 3,27
Net Profit (Loss)1 51,19 44,48 2,46 30,23 26,94 40,17 34,00
Net-Margin6 4,15 3,41 0,18 2,16 1,86 2,74 2,10
Cashflow1,7 49,50 47,30 113,30 97,50 41,30 109,00 85,00
Earnings per share8 0,73 0,65 0,02 0,42 0,38 0,58 0,51
Dividend per share8 0,29 0,00 0,00 0,00 0,15 0,00 0,00
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: KPMG

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Rhön-Klinikum
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
704230 DE0007042301 AG 924,08 Mio € 19.06.1991 Halten 9F2G86FM+GX
* * *
PE 2025e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
23,00 28,72 0,80 23,59 0,74 8,48 0,63
Dividends
Dividend '2022
in €
Dividend '2023
in €
Dividend '2024e
in €
Div.-Yield '2024e
in %
0,15 0,00 0,00 0,00%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
03.06.2025 08.05.2025 07.08.2025 07.11.2024 27.03.2025
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
-0,72%
13,80 €
ATH 32,12 €
+7,45% +12,57% +38,00% +32,69% +452,00%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2024          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2024 by Gereon Kruse #BGFL